McKesson (MCK) closed the most recent trading day at $807.33, moving +2.95% from the previous trading session.

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

McKesson (MCK) is rated a buy, offering capital growth and dividend potential, underpinned by robust top-line and EPS growth. MCK's diversified portfolio, role in oncology and collaboration with big pharma names like AbbVie, and investment-grade Fitch rating support its investment case despite negative equity. Valuation appears compelling, with MCK trading at a forward earnings multiple of ~18x and estimated 18–22% upside by March 2028.

McKesson's growth in specialty pharma, oncology services and tech-driven solutions is boosting earnings, but policy and execution risks remain in focus.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

McKesson (MCK) concluded the recent trading session at $747.53, signifying a -2.09% move from its prior day's close.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.